Obstetrics and Gynecology International

Review Article

Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy?

Table 1

Trials on adjuvant treatment for endometrial cancer.


Author(s)	Setting	Pts	Treatment arms	5-year PFS¹	5-year OS²	Comments
Author(s)	(Stage)	(No.)	Treatment arms	(%)	(%)	Comments

Randall et al. [49]	III-IV	396	WAI³	38	42	Treatment related deaths AP: 8 (4%), WAI: 5 (2%)
Randall et al. [49]	(optimally debulked)	396	AP⁴	50	55	Treatment related deaths AP: 8 (4%), WAI: 5 (2%)
Maggi et al. [50]	ICG3-III	345	External beam	63	69
			XRT⁵
			CAP⁶	63	66
Susumu et al. [52]	>50% myometrial invasion	385	Pelvic XRT	83.5	85.3	Superiority of CAP in high/intermediate risk (stICG3-IIIA) patients
Susumu et al. [52]	>50% myometrial invasion	385	CAP	81.8	86.7
Hogberg et al. [53]	IC-IIIC	367	Relvic XRT BT⁷	75	NR⁸
Hogberg et al. [53]	(confined to pelvis)	367	Pelvic RT BT Cx⁹	82	NR
Kuoppala et al. [51]	IAG3-IIIA	156	Pelvic XRT	18+ months	84.7	Intestinal complications demanding surgery
Kuoppala et al. [51]	IAG3-IIIA	156	Pelvic XRT CEP¹⁰	25+ months	82.1	XRT: 2 (2.7%), Pelvic XRT CEP: 8 (9.5%)

¹PFS, progression-free survival; ²OS, overall survival; ³WAI, whole abdominal irradiation; ⁴AP, doxorubicin and cisplatin; ⁵XRT, irradiation; ⁶CAP, cyclophosphamide, doxorubicin and cisplatin; ⁷BT, vaginal brachytherapy; ⁸NR, not reported; ⁹Cx, chemotherapy with AP or paclitaxel, epirubicin and carboplatin or paclitaxel and carboplatin; ¹⁰CEP, cyclophosphamide, epirubicin and cisplatin.